SEC Company Response from NRX Pharmaceuticals, Inc. (NRXP) (CIK 0001719406) (NRXP) — Nov 16, 2017
NRX Pharmaceuticals, Inc. (NRXP) (CIK 0001719406)
Date: Nov. 16, 2017 · CIK: 0001719406 · Accession: 0001654954-17-010788
AI Filing Summary & Sentiment
File numbers found in text: 333-220947
Show Raw Text
CORRESP 1 filename1.htm Blueprint EARLYBIRDCAPITAL, INC. 366 Madison Avenue | 8th Floor New York, NY 10017 November 16, 2017 VIA EDGAR Securities and Exchange Commission 100 F. Street, N.E. Washington, D.C. 20549 Attn: Amanda Ravitz Re: Big Rock Partners Acquisition Corp. (the "Company") Registration Statement on Form S-1 (File No. 333-220947) (the "Registration Statement") Dear Ms. Ravitz: In accordance with the provisions of Rule 460 under the Securities Act of 1933, the undersigned, as representative of the underwriters of the proposed offering of securities of Big Rock Partners Acquisition Corp., hereby advises that copies of the Preliminary Prospectus, dated November 14, 2017, were distributed on or about November 14, 2017, as follows: 235 to individual investors; 108 to FINRA members (which included 28 prospective underwriters and selected dealers); and 49 to institutions. The undersigned has been informed by the participating dealers that, in accordance with Rule 15c2-8 under the Securities Exchange Act of 1934, copies of the Preliminary Prospectus, dated November 14, 2017, have been distributed to all persons to whom it is expected that confirmations of sale will be sent; and we have likewise so distributed copies to all customers of ours. We have adequate equity to underwrite a “firm commitment” offering. Very truly yours, EARLYBIRDCAPITAL, INC. By: /s/ Steven Levine Name: Steven Levine Title: CEO